Gemcitabine News and Research

RSS

Gemcitabine is the active ingredient in a drug that is used to treat pancreatic cancer that is advanced or has spread. It is also used together with other drugs to treat breast cancer that has spread, advanced ovarian cancer, and non-small cell lung cancer that is advanced or has spread. It is also being studied in the treatment of other types of cancer. Gemcitabine blocks the cell from making DNA and may kill cancer cells. It is a type of antimetabolite

Update on Prolindac clinical development plan provided by Access Pharmaceuticals

ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), provided an update today on the Company's clinical development plan for ProLindac, a novel DACH platinum drug that has shown to be active in many solid tumor types in human clinical studies.

11 Sep 2009

Chk1 and Fbx6 play an important role for the regulation of response to chemotherapy

Cell cycle checkpoints act like molecular tripwires for damaged cells, forcing them to pause and take stock. Leave the tripwire in place for too long, though, and cancer cells will press on regardless, making them resistant to the lethal effects of certain types of chemotherapy, according to researchers at the Salk Institute for Biological Studies.

28 Aug 2009

Researchers reveal that genes contributing to drug resistance in NSCLC disease could be predicted

The genes that may contribute to drug resistance in non-small cell lung cancer (NSCLC) can be predicted. Researchers writing in the open access journal BMC Cancer found good correlation between genes believed to be involved in drug sensitivity and resistance and actual in vitro chemosensitivity.

26 Aug 2009

Genentech announces Phase III study results for Avastin (bevacizumab) in combination with chemo in HER2-negative breast cancer

Genentech, Inc. today announced that a Phase III study (RIBBON 2) of Avastin (bevacizumab) in combination with chemotherapy increased the time women with metastatic HER2-negative breast cancer whose initial chemotherapy had stopped working lived without the disease worsening (progression-free survival or PFS), compared to chemotherapy alone.

18 Aug 2009

U.S. District Court rules against Lilly regarding Gemzar patent

Eli Lilly and Company today announced that the U.S. District Court for the Eastern District of Michigan has granted a motion by Sun Pharmaceuticals for partial summary judgment.

17 Aug 2009

Array Biopharma reports Q4 and full year 2009 financials

Array reported revenue of $5.5 million for the fourth quarter of fiscal 2009, compared to revenue of $6.1 million for the same period in fiscal 2008. Array invested $21.3 million in proprietary research and development for the quarter to advance its seven wholly-owned drugs in clinical development and select discovery programs.

10 Aug 2009

New drug compound Salirasib brings hope to pancreatic cancer patients

Every year, 42,000 Americans are diagnosed with pancreatic cancer. Few live very long, and less than 5% are still alive five years after diagnosis.

20 Jul 2009

Discovery of critical marker of response to gemcitabine in pancreatic cancer

A protein related to aggressive cancers can actually improve the efficacy of gemcitabine at treating pancreatic cancer, according to a Priority Report in Cancer Research, published by researchers at Thomas Jefferson University.

4 Jun 2009

Trial results show better survival for gallbladder and bile duct cancer

Combining two chemotherapy drugs for advanced gallbladder and bile duct cancer improves survival by a third, according to results from a Cancer Research UK funded trial presented today at the American Society of Clinical Oncology (ASCO) conference.

2 Jun 2009

New research sheds light on ways to improve treatment for aggressive breast cancer

Changing the order that chemotherapy drugs are given to breast cancer patients before surgery makes treatment much more effective, according to trial results presented at the American Society of Clinical Oncology (ASCO) conference, today.

31 May 2009

Scientists shed new light on why pancreatic cancer drugs can fail

Cancer Research UK scientists led an international team of investigators who have discovered a new mechanism that may explain why pancreatic cancer patients are often resistant to a common chemotherapy treatment called gemcitabine, according to a study published in Science.

22 May 2009

New therapy for pancreatic cancer achieves tumor remission and prevents recurrence

Pancreatic cancer remains one of the deadliest cancers, but researchers may have found a combination therapy to reduce cancer stem cells and stop pancreatic cancer growth. Results will be presented at the American Association for Cancer Research 100th Annual Meeting 2009.

20 Apr 2009

Experimental insulin-like growth factor receptor inhibitor a clear clinical candidate for pancreatic cancer therapy

Researchers at Amgen are testing a fully human monoclonal antibody that inhibits the activity of insulin-like growth factors (IGF-1 and IGF-2) and appears to reduce pancreatic cancer cells in early testing, according to a report in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.

14 Apr 2009

Rexahn Pharmaceuticals starts phase II pancreatic cancer trial

Rexahn Pharmaceuticals, Inc. has announced that it has received FDA approval to begin Phase II trials for Archexin, the Company's leading cancer compound, for the treatment of pancreatic cancer.

24 Mar 2009

New trial targets kidney cancer drug sorafenib in bladder cancer

According to the American Cancer Society, 69,000 cases of bladder cancer were diagnosed nationwide last year with some 2,600 new cases in New Jersey.

16 Feb 2009

Scientists use non-invasive approach to watch chemo drug working inside the living body in real time

For many cancer patients, chemotherapy can be worse than cancer itself.

2 Feb 2009

Variations in mismatch repair genes predict prognosis in pancreatic cancer

Variations in mismatch repair genes can help predict treatment response and prognosis in patients with pancreatic cancer, according to research from The University of Texas M. D. Anderson Cancer Center presented today in advance of the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.

13 Jan 2009

Nonhormonal treatment regimens improve survival in patients with metastatic breast cancer

Nonhormonal treatment regimens, including anthracycline-based regimens and taxanes, have improved overall survival in women with advanced (metastatic or recurrent inoperable) breast cancer over the last 35 years, according to a systematic review published December 9 in the Journal of the National Cancer Institute.

10 Dec 2008

Protein enzyme BubR1 provides new understanding of processes behind cancer-cell survival and drug-resistance

A study of how one protein enzyme, BubR1, helps make sure chromosomes are equally distributed during mitosis might explain how the process of cell division goes so awry in cancer, according to researchers from Fox Chase Cancer Center.

17 Nov 2008

New drug substantially extends survival in pancreatic cancer

A new form of chemotherapy that destroys new blood vessels that grow around tumors has produced excellent results in a phase II trial of patients with inoperable pancreatic cancer, researchers report at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm.New drug substantially extends survival in pancreatic cancer

16 Sep 2008